What were the key takeaways from Assertio Holdings’s earnings call?

Did Assertio Holdings beat or miss consensus estimates last quarter?

What is Assertio Holdings's gross profit margin?

What is the market's earnings forecast for Assertio Holdings next quarter?

What does Assertio Holdings do and what are its main business segments?

What were the key takeaways from Assertio Holdings's earnings call?

What is Assertio Holdings's latest dividend and current dividend yield?

What factors drove the changes in Assertio Holdings's revenue and profit?

- **Rolvedon Reboot**: 2026 guidance reflects return to normalized sales post-label transition, with potential to exceed $100M annually.
- **Oncology Expansion**: Shifting focus to oncology therapeutics, with modest sales force expansion (~10-20%) to support new product launches.
- **Financial Resilience**: $63.4M cash balance and 2026 EBITDA guidance of $28M-$40M demonstrate strong financial footing for growth.
- **Strategic Shift**: Moving away from high-cost specialty product acquisitions, focusing on disciplined oncology BD opportunities.


**【CEO Summary Section】**
- **Rolvedon Revenue Opportunity**: CEO Mark Reisenauer highlighted Rolvedon as the core growth driver, noting its 2026 guidance reflects a return to normalized sales post-label transition. The product maintains leading market share in community oncology and has IP protection until 2039.
- **Commercial Platform Leverage**: The company will focus on expanding Rolvedon's reach through its existing commercial infrastructure, including field teams, market access, and patient services. This platform is also being evaluated for potential oncology acquisitions or partnerships.
- **Strategic Shift in Acquisitions**: Assertio is moving away from acquiring on-market specialty products due to rising competition and prices. Instead, it will pursue disciplined business development in oncology, targeting assets that align with its commercial strengths.

**【COO Operational Update】**
- **Rolvedon Integration Success**: Paul Schwichtenberg reported seamless transition to the Assertio label, with no disruption to patient supply. Q4 2025 sales were minimal due to channel inventory pull-through, but demand remained stable.
- **Growth Drivers**: New account additions in community oncology clinics are key to Rolvedon's expansion. The COO emphasized ongoing personnel and process enhancements to support growth while optimizing tail asset cash flow.
- **Commercial Infrastructure Strength**: The team's expertise in trade, distribution, and patient services positions Assertio to efficiently bring additional oncology products to market.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total product sales $12.8M (down 57% YoY) due to Rolvedon label transition. Adjusted EBITDA negative $4.1M (vs. +$3.4M YoY) due to working capital build. Cash balance $63.4M, supporting 2026 growth initiatives.
- **2026 Guidance**: Revenue $110M-$125M, driven by Rolvedon's normalized sales resumption in Q2. Adjusted EBITDA $28M-$40M, reflecting margin expansion from high-margin Rolvedon growth and cost savings.
- **Tailwind from Cost Control**: FY2025 SG&A down 39% YoY to $53.5M, with further savings expected in 2026 from reduced litigation expenses and restructuring.

**【Q&A Key Highlights】**
- **Oncology Strategy**: CEO emphasized focus on late-stage development assets in oncology, particularly therapeutics. Incremental investments in sales force (~10-20% growth) expected to support new product launches.
- **Rolvedon Growth Path**: COO noted Q1 2026 will see channel inventory settle, with Q2+ reflecting true demand. Long-term peak sales potential >$100M, driven by new account penetration.
- **Indocin Outlook**: CFO expects year-over-year decline due to generic competition, but will optimize pricing and mix to maintain profitability.
- **Divestiture Consideration**: CEO confirmed ongoing evaluation of non-core assets but no immediate plans to sell the company.


Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript

- **Rolvedon Dominance**: Q3 sales of $38.6 million (up 157% YoY) drove narrowed full-year guidance, with a 2-quarter pull-forward enabling uninterrupted patient supply despite a temporary cash flow decline.
- **Sympazan Expansion**: 7.7% YoY growth to $2.8 million, supported by new clinical data highlighting oral film benefits for swallowing-challenged patients.
- **Indocin Resilience**: 15.8% YoY decline offset by Q3 price favorability, underscoring competitive pricing strategies in generics.
- **Financial Stability**: $93.4 million cash balance and stable 72% gross margin position the company for Rolvedon relaunch in Q2 2026.

**【CEO Summary Section】**
- Mark Reisenauer, the new CEO, highlighted the company's progress with Rolvedon and Sympazan, emphasizing their potential as core growth assets. Rolvedon net product sales reached $38.6 million in Q3 2025, up from $15 million in Q3 2024, driven by a 2-quarter pull-forward to ensure seamless supply during the transition to a consolidated commercial labeler. Sympazan sales grew to $2.8 million, up from $2.6 million in the prior year quarter, supported by new clinical data presented at the American Neurological Association Meeting.
- The company narrowed its full-year 2025 guidance to product sales of $110-112 million and adjusted EBITDA of $14-16 million, reflecting the pull-forward impact and ongoing generic competition in Indocin.

**【CFO Financial Commentary】**
- Total product sales for Q3 2025 were $49.5 million, up from $28.7 million in Q3 2024, with Rolvedon accounting for $38.6 million. Sympazan sales increased 7.7% year-over-year, while Indocin sales declined 15.8% due to generic competition.
- Gross margin decreased modestly to 72% (from 74% in Q3 2024) due to the higher proportion of Rolvedon sales. Adjusted EBITDA rose to $20.9 million, up from $4.4 million in Q3 2024. The company ended Q3 with $93.4 million in cash, expecting a temporary cash decline in Q4 2025 and Q1 2026 before resuming sales of the newly labeled Rolvedon in Q2 2026.

**【Q&A Key Highlights】**
- **Rolvedon Strategy**: Management reaffirmed price stability and predictability, with no direct link between labor code changes and ASP. The same-day dosing data will be published in a major journal, supporting clinical differentiation.
- **Indocin Performance**: Despite generic competition, Q3 sales showed slight volume growth and price favorability, reflecting competitive pricing strategies.
- **Sympazan Growth**: The oral film delivery mechanism remains a key differentiator, with targeted digital and field promotions in high-prescribing areas.
- **Gross Margin Outlook**: A.J. Patel indicated stable gross margins in line with Q3 levels, with no immediate changes to the 72% range.

Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 net sales $28.8M, with Rolvedon and Sympazan growth offsetting Indocin decline.
- **Strategic Restructuring**: $2-3M annual SG&A savings from ceasing Otrexup, enabling focus on high-margin assets.
- **Profitability Boost**: Adjusted EBITDA up 80% YoY to $5.6M, driven by cost control and portfolio optimization.
- **Growth Catalysts**: Rolvedon demand +20% QoQ, Sympazan targeting $25-30M, and same-day dosing data poised for guideline inclusion.
- **Balance Sheet Flexibility**: $98M cash to pursue strategic transactions, with no debt maturities until 2027.

**【CEO Summary Section】**
- **Q2 2025 Financial Highlights**: Net product sales of $28.8 million, driven by Rolvedon ($16.1M) and Sympazan ($3.2M) growth. Indocin sales declined due to generic competition.
- **Business Strategy Progress**: 
  - **Transformation Phase**: 5 core objectives (legal exposure reduction, corporate restructuring, growth asset prioritization, noncore divestments, strategic transactions) nearing completion.
  - **Legal Resolution**: Settled multiple lawsuits, reducing legal costs and freeing resources for core business.
  - **Portfolio Optimization**: Ceased Otrexup commercialization to focus on Rolvedon and Sympazan, with $2-3M annual SG&A savings.
- **Growth Catalysts**: 
  - Rolvedon demand up 20% QoQ, benefiting from expanded provider base and in-person sales.
  - Sympazan prescriptions growing from new prescribers, targeting $25-30M net sales in coming years.
  - Same-day dosing data interest increasing, with potential NCCN guideline inclusion by mid-2026.

**【CFO Financial Commentary】**
- **Q2 Financials**: 
  - GAAP net loss: $16.4M (vs. $3.7M prior year), driven by one-time charges ($9.2M Assertio Therapeutics divestiture, $3.8M Otrexup cessation).
  - Adjusted EBITDA: $5.6M (vs. $3.1M prior year), reflecting cost efficiencies.
  - Cash balance: $98.2M (up from $87.3M Q1), supporting strategic flexibility.
- **Updated Guidance**: 
  - Net product sales: $108M-$118M (narrowed from $108M-$123M).
  - Adjusted EBITDA: $11M-$19M (low end raised due to Otrexup cessation benefits).

**【Q&A Key Highlights】**
- **Rolvedon Sales Transparency**: Excluding $5.4M returns reserve adjustment, "true" Rolvedon sales were $10.7M. Strong clinic demand (20% QoQ growth) positions for H2 execution.
- **Otrexup Impact**: No IP remaining; strategic divestment to redirect resources to core assets. Top-line loss offset by $2-3M annual SG&A savings.
- **Balance Sheet Strength**: $98M cash and no debt maturities until 2027, supporting 2025 strategic transaction pursuit.
- **Sympazan Growth**: Accelerated promotion efforts targeting $25-30M net sales, driven by provider awareness and patient access improvements.

Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript

- **Q1 2025 Performance**: Net sales $26M, tracking to $108-123M annual target. Rolvedon recovery expected from Q2, Sympazan prescriptions +6.5% YoY.
- **Legal Risk Mitigation**: Settled legacy lawsuits, transferred opioid liabilities, reducing legal costs by $2-3M/year.
- **Growth Drivers**: 
  - Payer expansion with Cigna to unlock commercial and hospital Rolvedon sales.
  - Same-day dosing trial results submitted for NCCN guideline inclusion in 2026.
  - Actively pursuing strategic acquisitions for specialty pharma growth.
- **Risks**: Indocin generics expected to reduce market share, Rolvedon ASP erosion ongoing.

**【CEO Opening Remarks】**
- Q1 2025 net product sales: $26 million (slightly ahead of plan), tracking to full-year guidance of $108-123 million.
- Rolvedon sales impacted by Q4 2024 stocking activity, but expected to improve from Q2 onward.
- New payer coverage with Cigna and expanded coverage in H2 2025 to drive growth.
- Sympazan prescriptions up 6.5% YoY, Indocin stable despite generic competition.

**【CFO Financial Highlights】**
- Q1 2025 GAAP net loss: $13.5 million (vs. $4.5 million loss in Q1 2024).
- Adjusted EBITDA: $0.2 million (vs. $7.4 million in Q1 2024), reflecting lower sales and gross margin.
- Cash balance: $87.3 million as of March 31, 2025 (down from $100.1 million at year-end).
- Debt remains unchanged at $40 million (6.5% convertible notes maturing 2027).

**【Strategic Priorities】**
- **Legal Risk Mitigation**: Settled multiple legacy lawsuits, transferred opioid-related liabilities to ATIH, reducing legal costs by ~$2-3 million annually.
- **Portfolio Optimization**: Divesting non-core assets (e.g., Assertio Therapeutics), reallocating resources to Rolvedon and Sympazan.
- **Growth Initiatives**: 
  - Expanding Rolvedon into hospital settings via commercial payer expansion.
  - Same-day dosing trial results submitted for peer-reviewed publication, targeting NCCN guideline inclusion in 2026.
  - Actively pursuing strategic acquisitions to bolster specialty pharma portfolio.

**【Q&A Key Takeaways】**
- **Rolvedon Pricing**: ASP erosion expected, but managed through smart contracting and new customer additions.
- **Indocin Generics**: 2-3 generics expected in 2025, leading to incremental market share loss.
- **Legal Litigation**: Minimal risk of parent company liability post-Assertio Therapeutics divestiture.
- **Guidance Integrity**: 2025 financial outlook excludes potential M&A contributions.
- **Regulatory Impact**: Tariffs and drug pricing executive orders unlikely to materially affect U.S. operations.


Assertio (ASRT)-12 May 25-2025 Q1 Earnings call transcript

- **2025 Strategic Focus**: 4 priorities - simplify, grow Rolvedon/Sympazan, reduce legal risk, deploy capital
- **2024 Financial Resilience**: $120.8M sales, $17.1M EBITDA despite $4.2M Indocin write-downs
- **Rolvedon Growth**: $60M+ sales, 60%+ community oncology share, Q4 ASP +2%
- **Acquisition Outlook**: >50% chance of deal in 2025 with oncology focus
- **Legal Progress**: 140+ opioid cases dismissed, OpEx savings potential
- **Sympazan Uptick**: Jan 2025 prescriptions highest since acquisition with field rep expansion

**【CEO Opening Remarks】**
- 2024 characterized as a **year of stabilization**, transitioning from Indocin (lost exclusivity) to Rolvedon as lead asset. 
- 2025 defined as **year of transformation** with 4 strategic priorities:
  1. Simplify structure/processes
  2. Focus on growth assets (Rolvedon, Sympazan)
  3. Reduce legal exposure
  4. Deploy capital accretively
- 2024 achievements: 
  - Exceeded $60M Rolvedon sales, 60%+ community oncology share
  - Managed Indocin decline ($26.8M sales vs. $35M prior)
  - Completed Rolvedon same-day dosing trial
  - Added CCO & CTO roles
  - Strong cash flow ($26.4M) & balanced sheet

**【CFO Financial Review】**
- **Q4 2024 Results**:
  - Product sales: $29.6M (vs. $28.7M Q3)
  - Rolvedon: $15.4M (+$0.4M vs. Q3)
  - Indocin: $5.5M (-$0.2M vs. Q3)
  - Gross margin: 61% (down from 74% Q3 due to Indocin inventory write-downs)
  - Adjusted EBITDA: -$0.5M (vs. +$5.3M Q3)
  - GAAP net loss: $10.5M (vs. -$2.9M Q3)
- **Full Year 2024**:
  - Total sales: $120.8M (high end of guidance)
  - Rolvedon: $60.1M (vs. $50M+ target)
  - Indocin: $26.8M (vs. $20-25M target)
  - Adjusted EBITDA: $17.1M (vs. $20M low-end guidance)
  - Key drivers: $4.2M Indocin inventory write-downs, $1M+ litigation costs

**【Q&A Highlights】**
1. **2025 Guidance Range**:
   - Sales: $108-123M
   - EBITDA: $10-19M
   - Key variables: Indocin erosion pace, Rolvedon commercial expansion
2. **Acquisition Outlook**:
   - >50% likelihood of deal in 2025
   - Focus on oncology/specialty care assets with omnichannel fit
3. **Legal Progress**:
   - 140+ opioid cases dismissed
   - Ongoing MDL process but optimistic trajectory
   - OpEx savings potential as cases resolve
4. **Rolvedon ASP**:
   - Q4 ASP up 2% vs. Q3
   - Driven by disciplined pricing & volume growth
5. **Sympazan Momentum**:
   - Field reps added in Q4
   - Jan 2025 prescriptions at highest level since acquisition
   - Testing contract sales force expansion

Actual											6	1.6144	-1.7658	5.6075	2.3855	-3.7424	1.5882	2.4782	5.7	4.2	3.3	4.8	4.35	2.85	0.15	1.65	-0.75	-0.6	-0.45	-1.65	-2.1	-2.55	1.65	-1.86
Forecast											-4.8	-5.1	-1.8	-2.1	1.2	1.8	1.8	1.2	1.2	1.5	1.055	8.58	2.715	2.785	1.425	0	-0.15	-0.48	-0.69	-0.66	-0.9	-1.35	-1.275	-3.11
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+225.00%	+131.65%	+1.90%	+367.02%	+98.79%	-307.91%	-11.77%	+106.52%	+375.00%	+180.00%	+212.80%	-44.06%	+60.22%	+2.33%	-89.47%	0.00%	-400.00%	-25.00%	+34.78%	-150.00%	-133.33%	-88.89%	+229.41%	+40.19%

ASRT

ASRT fundamentals

ASRT Q4 2025 Earnings

Earnings Call

You can ask Aime

ASRT

ASRT fundamentals

ASRT Q4 2025 Earnings

Earnings Call

ASRT Earnings Call Summary for Q4/20254:30 PM on Mar 16, 2026

ASRT Earnings Call Summary for Q3/20254:30 PM on Nov 10, 2025

ASRT Earnings Call Summary for Q2/20254:30 PM on Aug 11, 2025

ASRT Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

ASRT Earnings Call Summary for Q4/20244:30 PM on Mar 12, 2025

You can ask Aime